Connect
MJA
MJA

Biosimilars in inflammatory bowel disease

Gregory T Moore
Med J Aust 2016; 205 (7): 294-295. || doi: 10.5694/mja16.00775
Published online: 3 October 2016

Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited

The management of inflammatory bowel disease has undergone major changes in the last decade with the availability on the Pharmaceutical Benefits Scheme (PBS) of targeted biological therapies. The first of these was the anti-tumour necrosis factor α (anti-TNF-α) monoclonal antibody infliximab, followed by another anti-TNF-α antibody adalimumab, and, more recently, the first gut-specific T-cell trafficking inhibitor vedolizumab, an anti-α-4 β-7 integrin monoclonal antibody. These drugs have resulted in a shift in the management paradigm from symptom control and the minimisation of exposure to corticosteroids to now aiming for healing of the intestinal mucosa, prevention of damage and subsequent disability.1

  • Gregory T Moore1,2

  • 1 Monash Health, Clayton, VIC
  • 2 Monash University, Clayton, VIC

Correspondence: gregory.moore@monash.edu

Competing interests:

I am the current chair of the Australian Inflammatory Bowel Disease Association of the Gastroenterological Society of Australia, a board member of Crohn’s & Colitis Australia, and have been on advisory boards and/or received speaker fees from the following manufacturers of biological medicinesAbbVie, Janssen, Hospira and Takeda.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.